Frozen Platelets-Development and Future Directions.
Cryopreserved platelets
DMSO platelets
Frozen platelets
Journal
Transfusion medicine reviews
ISSN: 1532-9496
Titre abrégé: Transfus Med Rev
Pays: United States
ID NLM: 8709027
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
24
07
2020
revised:
10
09
2020
accepted:
10
09
2020
entrez:
15
12
2020
pubmed:
16
12
2020
medline:
21
10
2021
Statut:
ppublish
Résumé
Storage requirements and outdating of platelets represent a continued challenge for blood banks. These hurdles are confounded for rural area hospitals or in military deployments. Over 60 years of research and development into frozen platelets have generated a stable and reproducible product. Valeri's method to freeze platelets in 6% dimethyl sulfoxide (DMSO) and storage at -80°C allows for long-term storage alleviating burdens placed on blood banks. Clinical studies show that frozen platelet transfusions are safe with no related thrombotic or other serious adverse events. There are ongoing efforts to demonstrate cryopreserved platelet (CPP) superiority in efficacy studies designed in trauma or cardiac surgery patients. Technical advances in CPP manufacturing including closed system manufacturing, applications of pathogen reduction technology and potency standard characterization add to the appeal of CPP as an alternative to traditional liquid-stored platelets (LP) in settings of supply shortages, mass casualty, active bleeding, rapid provision of HLA-compatible platelets, and remote care.
Identifiants
pubmed: 33317698
pii: S0887-7963(20)30054-7
doi: 10.1016/j.tmrv.2020.09.008
pii:
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
286-293Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.